Table 2 Summary of response rates.

From: Propensity score analysis of high-dose rate brachytherapy, immune checkpoint inhibitors, and docetaxel in second-line advanced NSCLC treatment

Best overall response, n (%)

Brachytherapy + ICIs + Docetaxel

(n = 21)

ICIs + Docetaxel

(n = 21)

P

CR

0

0

–

PR

9

6

0.521

SD

6

7

> 0.999

PD

6

8

0.742

ORR

9

6

0.521

DCR

15

13

0.742

  1. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.
Back to article page